Robert Hazlett

Stock Analyst at BTIG

(1.29)
# 3,641
Out of 5,042 analysts
23
Total ratings
39.13%
Success rate
-1.45%
Average return

Stocks Rated by Robert Hazlett

Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21$24
Current: $5.86
Upside: +309.56%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $60.10
Upside: -0.17%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7$14
Current: $1.82
Upside: +669.23%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200$1,000
Current: $6.37
Upside: +15,599.08%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62$98
Current: $129.55
Upside: -24.35%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96$60
Current: $7.95
Upside: +654.72%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $6.28
Upside: +903.18%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $9.82
Upside: +195.32%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.64
Upside: +1,585,265.85%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26$6
Current: $3.03
Upside: +98.02%
Initiates: Buy
Price Target: $18
Current: $11.13
Upside: +61.73%